COVID-19 Management in Patients with Sarcoidosis
For COVID-19 patients with sarcoidosis requiring oxygen support, use dexamethasone 6 mg once daily for up to 10 days—the same standard dose as for patients without sarcoidosis. The presence of sarcoidosis does not change the fundamental COVID-19 steroid dosing strategy, and existing sarcoidosis immunosuppression should generally be continued during COVID-19 treatment.
Dexamethasone Dosing Algorithm
For Hospitalized COVID-19 Patients with Sarcoidosis:
Requiring oxygen, non-invasive ventilation, or mechanical ventilation:
- Dexamethasone 6 mg once daily (oral or IV) for up to 10 days 1, 2
- This is the mortality-reducing dose from the RECOVERY trial—do NOT increase the dose simply because the patient has sarcoidosis
- Alternative: Methylprednisolone 0.5-1 mg/kg/day for 3-7 days if dexamethasone unavailable 1
NOT requiring supplemental oxygen:
- Do NOT give corticosteroids for COVID-19 3
- Continue baseline sarcoidosis steroids only if already prescribed
Critical illness (invasive ventilation/vasopressors):
- Dexamethasone 6 mg daily remains standard 1
- Add remdesivir and consider combination antiviral therapy
- Consider adding tocilizumab or baricitinib if COVID-19-related inflammation persists despite steroids 1
- Only escalate steroids if co-infections are excluded 1
Management of Baseline Sarcoidosis Medications
Continue existing sarcoidosis immunosuppression during COVID-19:
- Maintain baseline corticosteroids at the lowest effective dose to control sarcoidosis and prevent adrenal insufficiency 4
- Continue methotrexate, azathioprine, mycophenolate if necessary for sarcoidosis control 4
- Key finding: Patients with sarcoidosis on immunosuppression had DECREASED risk of critical COVID-19 (OR 0.45,95% CI 0.31-0.65) 5
For symptomatic COVID-19:
- Temporarily hold DMARDs (except IL-1/IL-6 inhibitors) until COVID-19 symptoms resolve 4
- Continue glucocorticoids but attempt to reduce to lowest effective dose 4
- Resume held medications after complete resolution of COVID-19 symptoms 6
Critical Considerations
Avoid steroid dose escalation pitfalls:
- Over 20% of COVID-19 patients receive inappropriately high dexamethasone doses (>6 mg daily) 7
- Higher doses do NOT improve outcomes and increase adverse effects including hyperglycemia, infections, and HPA axis suppression 8, 9
- Glucocorticoid-induced hyperglycemia occurs in 32.3% of patients receiving systemic steroids, with diabetes persisting in 18.6% 8
Monitoring requirements:
- Check blood glucose regularly—expect hyperglycemia requiring insulin in many patients 8
- PCP prophylaxis if receiving ≥20 mg methylprednisolone equivalent for ≥4 weeks 10
- Proton pump inhibitor for GI prophylaxis with grade 2-4 pneumonitis on steroids 10
- Calcium and vitamin D supplementation with prolonged steroid use 10
Post-COVID-19 steroid management:
- Standard 10-day dexamethasone course (6 mg daily) does NOT cause clinically significant HPA axis suppression 8
- No routine cortisol testing needed after standard COVID-19 dexamethasone regimen 8
- If steroids given >3 weeks, consider HPA axis evaluation 12 weeks post-discharge 8
Sarcoidosis flare risk:
- COVID-19 infection itself may trigger sarcoidosis flare based on case reports 6
- Paradoxically, continuing immunosuppression appears protective against severe COVID-19 5
- Monitor for new/worsening sarcoidosis symptoms during recovery
Evidence Strength
The recommendation for dexamethasone 6 mg daily is based on the landmark RECOVERY trial showing 28-day mortality reduction in oxygen-requiring patients (rate ratio 0.82,95% CI 0.72-0.94) 2. The 2025 ECIL-10 guidelines specifically endorse this regimen for COVID-19 patients with hematologic conditions on immunosuppression 1, and the 2021 ERS guidelines provide strong recommendations for corticosteroids in oxygen-requiring COVID-19 patients 3. Importantly, real-world data from 84 hospitalized sarcoidosis patients with COVID-19 showed those on immunosuppression had better outcomes 5, contradicting early pandemic concerns about continuing these medications.